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VasculogenesisThe purine nucleoside adenosine is an important regulator within the cardiovascular system, and throughout the
body. Released in response to perturbations in energy state, among other stimuli, local adenosine interacts with 4
adenosine receptor sub-types on constituent cardiac and vascular cells: A1, A2A, A2B, and A3ARs. These G-protein
coupled receptors mediate varied responses, from modulation of coronary ﬂow, heart rate and contraction, to
cardioprotection, inﬂammatory regulation, and control of cell growth and tissue remodeling. Research also unveils
an increasingly complex interplay between members of the adenosine receptor family, and with other receptor
groups. Given generally favorable effects of adenosine receptor activity (e.g. improving the balance between
myocardial energy utilization and supply, limiting injury and adverse remodeling, suppressing inﬂammation), the
adenosine receptor system is an attractive target for therapeutic manipulation. Cardiovascular adenosine
receptor-based therapies are already in place, and trials of new treatments underway. Although the complex
interplay between adenosine receptors and other receptors, and their wide distribution and functions, pose
challenges to implementation of site/target speciﬁc cardiovascular therapy, the potential of adenosinergic
pharmacotherapy canbemore fully realizedwith greater understanding of the roles of adenosine receptors under
physiological and pathological conditions. This review addresses some of the major known and proposed actions
of adenosine and adenosine receptors in the heart and vessels, focusing on the ability of the adenosine receptor
system to regulate cell function, retaliate against injurious stressors, andmediate longer-term adaptive responses.
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Adenosine exerts a range of generally beneﬁcial effects in the heart
and vessels [1,2], and has been described as a ‘retaliatorymetabolite’ [3].
This nucleoside is released from metabolically compromised cells to
mediate responses that appear directed at optimizing the balance
between energy utilization and generation (Fig. 1), thus linkingFig. 1. Simpliﬁed depiction of proposed regulatory roles of adenosine and ARs in modulat
panel), and the impact of ARs in ameliorating injury and promoting adaptation (lower pane
Receptor involvement (identiﬁed in either animal or human studies) is shown.physiological control (via ARs) to cellular energy state. From evolution-
ary and teleological viewpoints, emergence of adenosine sensitivity is an
effective way for cells to sense and respond to acute or prolonged shifts
in energy balance. Adenosine is also released in response to physiolog-
ical and pathological stimuli not necessarily linked to energy state. In
this review select roles of cardiovascular ARs are considered within a
hierarchy of regulation, retaliation and adaptation. Under physiologicaling/optimizing the balance between myocardial energy ‘supply’ and ‘demand’ (upper
l) during and following myocardial insult. Responses may be modiﬁed in disease states.
1415J.P. Headrick et al. / Biochimica et Biophysica Acta 1808 (2011) 1413–1428conditions or mild perturbations, ‘regulatory’ effects of adenosine may
optimize myocardial energy supply and demand, enhancing O2 and
substrate delivery and modulating energy use through ﬁne-tuning of
adrenergic sensitivity, heart rate and conduction (Fig. 1). There is
experimental evidence that endogenous adenosine can optimize the
balance between myocardial energy generation and expenditure,
improving the efﬁciency of O2 utilization [4,5]. With more severe insult
such as ischemia or hypoxia, cells may in a sense ‘retaliate’ via receptor-
mediated effects of greatly enhanced adenosine release, which triggers
cytoprotective responses that induce short- and longer-term resistance
to stress (Fig. 1). Finally, ARs play a role in more sustained ‘adaptive’
changes in myocardial/vascular structure and function. These differing
responses are beneﬁcial, yet AR responses may be modiﬁed in different
pathologies, a dysfunction that can potentially contribute to shifts in
resistance to and progression of disease. However, the roles of
adenosine and ARs in healthy and diseased humans are yet to be fully
delineated, with the bulk of research evidencing important regulatory
roles for ARs in a variety of animal models.1.1. Signal generation
Adenosine can be considered a metabolic signal, released from cells
to activate ARs in response to energy perturbations or imbalances in O2
supply vs. demand. This adenosine signal can be linked simply to net
hydrolysis of adenine nucleotides, however loss of purine moieties is a
costly approach to cell signaling. Cells thus possess systems for
maintaining essential adenine nucleotide pools, permitting controlled
release of low regulatory quantities of adenosine whilst ensuring rapid
recapture (thus localizing effects to sites of stress or injury).
Adenosine is generated through 2 primary paths — hydrolysis of
5′-AMP or metabolism of s-adenosylhomocysteine. The pathway
involving 5-AMP, which is derived primarily from adenine nucleotides
but also potentially from cAMP, is highly regulated, coupled to
bioenergetic state, and is the most important in generating regulatory
adenosine [6,7]. The hydrolysis of 5′-AMP can occur either intracellu-
larly or via ecto-nucleotidases. Several studies identify the intracellular
5′-AMP pool as the major source of adenosine release under baseline
conditions and during ischemia or hypoxia [8–10]. Nonetheless, studies
of ecto-nucleotidase inhibition or knockout highlight the physiological
importance of this external source of adenosine.
Within the cell the myokinase (adenylate kinase) equilibrium
facilitates elevations in substrate for adenosine (5′-AMP) as a function
of [ADP]2 (which rises with reductions in the Gibbs free energy of ATP
hydrolysis). In addition, regulation of 5′-nucleotidases during de-
energization (via shifts in ATP, ADP, Pi, andMg2+)may further promote
activity. The adenosine kinase reaction, in turn, effectively and rapidly
re-captures adenosine into the nucleotide pool, and its inhibition is key
to adenosine release during de-energization, an effect potentially
mediated by Pi [7,11,12]. Through these mechanisms, adenosine
formation is sensitized to perturbations in energy state, yet can be
independently regulated through control of enzymatic pathway
activity.
As noted above, while the majority of adenosine derives from
intracellular paths, ecto-nucleotidase dependent formation appears
particularly important in cardiovascular regulation. CD73 activity has
been shown to be critical to cardioprotection [13,14], thromboregula-
tion and inﬂammation [15,16], neointima formation [17], and
inhibition of inﬂammatory/immune sequelae of cardiac transplanta-
tion [18]. Interestingly, these responses all involve modulation of
inﬂammatory or vascular cells, perhaps reﬂecting a speciﬁc role for
extracellular adenosine generation in endothelial/inﬂammatory con-
trol. Intra- and extracellular sources may be relevant in different cell
types under different conditions, generating threshold adenosine
levels required for local AR activation. The ecto-nucleotidase pathway
will speciﬁcally generate adenosine within the extracellular compart-ment, in close proximity to surface receptors and local inﬂammatory
cell types.
Adenosine not recaptured via cellular re-uptake and the kinase
reaction is deaminated to inosine, which is additionally generated in
IMP hydrolysis. Inosine also interacts with A1 and A3ARs, whereas
analysis of human A2A and A2B sub-types reveals no substantial
agonism. Since extracellular inosine accumulates to much higher
levels than adenosine during ischemia or hypoxia, intrinsic A1 and
A3AR activity under these conditions should involve a major inosine-
dependent component. Differing metabolism patterns for 5′-AMP and
IMP also leads to potentially distinct patterns of AR agonism by
inosine vs. adenosine. Olsson and Pearson suggest that IMP catabolism
is dominant in cells that primarily generate ATP via anaerobic
glycolysis [1], and studies reveal signiﬁcant generation of inosine
from IMP rather than 5′-AMP in ischemic or hypoxic hearts. Inosine
and adenosine also compete for nucleoside transport, thereby
enhancing each other's extracellular levels (and thus signaling
capacity). The roles and importance of inosine-dependent AR
activation warrant further investigation.1.2. Mediation of adenosine responses — the ARs
Adenosine modiﬁes cellular function via membrane-bound A1,
A2A, A2B, and A3ARs [19]. It may also impact via energy substrate
effects. Although generally considered as independent functional
‘monomers’, recent work reveals that these receptors can hetero-
dimerize with other GPCRs, and there is evidence of signiﬁcant
receptor cross-talk in AR responses. The A1AR can heterodimerize
with P2Y1 or D1 dopamine receptors [20,21], and the A2AARwith P2Y,
D2 dopamine and mGLU5 receptors [22–24]. While these studies
assess interactions in recombinant expression models other work
does conﬁrm existence of oligomers in vivo, albeit in non-cardiac
tissue [25]. Although of considerable interest, the expression and roles
of endogenous receptor complexes in cardiovascular cells remain
poorly deﬁned.
The AR sub-types themselves also interact, whichmay be important
in the expression of cardiovascular responses. For example, A1ARs may
counter A2AR mediated vasodilatation [26], anti-adrenergic actions of
A1ARs are counteracted by A2AARs [27], and there is evidence of
interaction between A1, A2A and A2BARs inmediating cardiac protection
[28]. These effects potentially reﬂect receptor dimerization, since A1/A2A
heteromers occur in other tissue [29]. However, these heteromers have
not been studied in cardiovascular cells. In terms of cardiac protection,
ARs also interact with opioid receptors to limit injury and cell death
during ischemia-reperfusion [30]. Thus, theAR systemexhibits complex
interactions between its own members and with other GPCRs. This
might be predicted given that purinergic receptors represent one of the
earliest signaling systems [31], allowing protracted evolution and
reﬁnement of complex signal linkages between cellular function and
energy state.2. Regulation
Within the heart adenosine is attributed with regulatory functions
that include control of cardiac contractility/adrenergic responsive-
ness, impulse generation and conduction, coronary vascular tone, and
cardiac substrate utilization. These are addressed here in more detail.
Other regulatory functions may be directed at adaptation (e.g.
regulation of ﬁbroblast activity) or protection, and are addressed in
subsequent sections. Adenosine also plays a key role in regulating
inﬂammatory responses in a wide range of cells [32]. However, full
coverage of the latter is beyond the scope of this review, and thus
aspects of inﬂammatory control relevant to the heart and vessels are
addressed within the context of speciﬁc AR responses.
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Adenosine primarily modiﬁes cardiac contractility in an indirect
fashion, through themodulation of adrenergic responses [33]. The anti-
adrenergic effects of adenosine in animal models are mediated via
A1ARs, involve Gαi inhibition of PKA activation by ß-adrenoceptors
[33,34], and modulation of ß1-adrenoceptor stimulated Gs cycling [35].
Dobson and colleagues also show that the A1AR can attenuate ß-
adrenergic responses in a PKC-dependent process [36,37] involvingGβγ
and PLC activation of PKC-ε [38]. Distal targets include p38-MAPK
(which may play a role in modifying contractile responses) and HSP27
(implicated in cardioprotective responses). There is also evidence
for a modest direct inotropic effect of A2AARs in mammalian myo-
cytes [39,40], involving Ca2+ transient augmentation by cAMP/PKA-
dependent and PKC-independent signals [37]. The A2AAR may addi-
tionallymodify contractilityby countering theanti-adrenergic actions of
A1ARs [27,35]. The relevance of these differing inotropic actions in
human myocardium remains to be established.
In addition to effects on cardiomyocyte adrenoceptor responses,
adenosine and A1ARs inhibit release of noradrenaline from cardiac
nerves [41], reducing levels during ischemia and reperfusion [42,43].
These effects are shown to be protective [42], and will contribute (with
the abovementioned responses) to inhibition of cardiac activation
during periods of enhanced adenosine release. Differing A1/A2A-
dependent actions of adenosine may act to limit cardiac over-
stimulation, matching metabolic capacity of the tissue with the level of
adrenergic drive. However, the relevance of modest A2AR-dependent
inotropy remains to be established, and the high (indeed non-selective)
μmolar levels of potent A2AAR agonist (CGS21680) required to elicit
measurable shifts in Ca2+ transient and contractility [37] indicate the
response would only be engaged at exceedingly high levels of
extracellular adenosine. While speculative, A2AARs may modestly
augment contractility in ischemic or hypoxic hearts (when such levels
are achieved). The ability of A2AARs to counter A1AR-inhibition of
adrenergic responses could also enhance contractility under such
conditions— aneffect estimated to represent ~2/3 of the total contractile
response to the A2AAR [27]. However, again these responses are elicited
at high CGS21680 levels, an agonist 50- to 100-fold more potent than
adenosine at A2AARs. One would thus not predict appreciable (direct or
indirect) A2AAR effects with b10 μM adenosine— levels rarely achieved
except in severe ischemia or hypoxia. On the other hand, the A1AR-
mediated effect is engaged at much lower agonist levels and pre-
dominates, limiting adrenergic activation of metabolism and contractil-
ity in compromised myocardium.
2.1.1. Pathobiology
There is some evidence of shifts in AR control of inotropy and
adrenergic function in disease models. For example, Dobson and
colleagues found that A1AR-mediated anti-adrenergic responses in
rats are impaired with pressure-overload hypertrophy [44]. Similarly,
Tang et al. found that effects of A1 and A2AARs on cardiomyocyte
adrenergic responsiveness are inhibited or abolished in hypertensive
animals, independently of hypertrophy [45]. Repression of A1AR-
mediated inhibitory effects in settings of hypertrophy or hypertension
could enhance the vulnerability of hearts to chronic shifts in
sympathetic activity. As outlined in a later section, alterations in AR
expression and function may play a role in the contractile dysfunction
(and remodeling) that occurs in hypertrophic and failing hearts.
The inhibitory effects of ARs may also underlie repression of
adrenergic signaling and responsiveness in ischemic or hypoxic
myocardium. A study by Burgdorf et al. supports the idea that post-
ischemic repression of cardiac sympathetic neurotransmission (neuronal
stunning) involves intrinsic A1AR activity [43]. In other work, Gergs et al.
identiﬁed an unexpected positive inotropic response to adenosine in
atrial tissue from 25% of coronary heart disease patients [46]. The
response was sensitive to A1AR antagonism, reﬂecting an overlookedA1AR-dependent inotropy in some subjects. Its relevance is not clear at
this stage. Though not a disease state, the process of aging predisposes to
cardiovascular diseases and is also associated with shifts in AR-mediated
anti-adrenergic and inotropic actions. Speciﬁcally, age impairs adrenergic
sensitivity of rodent hearts in part via enhanced A1AR activity [47,48].
Age also modiﬁes the release of adenosine from hearts, myocytes and
ﬁbroblasts [49–52]. This highlights the importance of addressing AR
responses in older and diseased tissues rather than young healthy
subjects, as both age and disease impact on AR functionality (whichmay
be relevant to age-related cardiovascular diseases). Analysis of AR-
mediated anti-adrenergic effects in human myocardium is required to
clarify the potential physiological and clinical importance of this control
mechanism.
2.2. Cardiac impulse generation and conduction
One of the earliest observed actions of adenosine was slowing of
heart rate and impulse conduction [53]. Adenosine inhibits impulse
generation in supraventricular tissue (SA node, AV node) and the His-
Purkinje system. Negative chronotropy is A1AR-mediated, and
involves inactivation of the inwardly rectifying K+ current (IK,Ado or
IK,Ach), together with inhibition of the inward Ca2+ current (ICa) and
the ‘funny’ hyperpolarization-activated current (If) [54]. Indirect anti-
adrenergic effects of the A1AR contribute through modifying If and
inhibiting activation of ICa. The relative roles of these currents differ in
speciﬁc tissues. For example, in vivo data supports a greater role for If
in His-Purkinje ﬁbers vs. SA nodal tissue [55]. Tissue differences may
reﬂect differential K+ channel expression: the IK,Ado is prevalent in
atrial vs. ventricular myocytes, and adenosine thus has minor if any
direct effects on ventricular action potentials. In atria adenosine also
exerts modest inhibition of the basal L-type Ca2+ current (ICa,L), but
not the T-type current (ICa,T). Adenosine can also activate ventricular
IKATP, though the functional relevance of this effect is not clear at
present. These alternate mechanisms may account for the ~50%
component of adenosine-induced bradycardia that appears resistant
to IK,Ado deletion [56].
Adenosine delays impulse conduction in addition to generation,
prolonging P–R and A–H intervals and generating AV block. The
dromotropic effects appear primarily restricted to the AV node with
no effects on the H–V interval. This negative dromotropic action has
been attributed to A1AR activation of IK,Ado and inhibition of ß-
adrenergic activation of ICa,L. However, since adenosine has a
negligible impact on the basal L-type Ca2+ current in AV nodal cells
(in the absence of adrenergic stimulation), the indirect mechanism
will only contribute to AV conduction delay under conditions of
sympathetic activation. Moreover, since A1AR agonism prolongs AV
conduction in mice lacking IK,Ado [56], the importance of this current
to the response is unclear. The A1AR has also been shown to slow
conduction in ischemic myocardium in a pertussis sensitive G-protein
dependent manner [57], and there is evidence that low levels of
adenosine mediate negative dromotropy via a K+ current with
delayed rectifying properties [58].
Interestingly, Rubio and colleagues provide evidence that the
dromotropic action of intravascular adenosine is initiated via endothe-
lial ARs and transduced by NO and prostaglandins [59]. These data raise
the possibility of differing electrophysiological responses to locally
produced vs. exogenously applied or circulating adenosine. This is
consistentwith the observation of Rajasekaran et al. that adenosine and
superoxide delay AV conduction synergistically via an NO-dependent
mechanism independent of IK,Ado [60]. This adenosine/radical synergism
is speculated to contribute to arrhythmogenesis in post-ischemic tissue,
where both triggers are elevated.
2.2.1. Pathobiology
As with anti-arrhythmic drugs, adenosine has the potential to be
either anti- or pro-arrhythmic, for example inducing atrial ﬂutter or
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shortened action potential and refractory period due to IK,Ado
activation. Studies support an important role for locally produced
adenosine in mediating arrhythmias or slowing rate and conduction
under pathological conditions in animal models [57,61–63]. Both
animal and human studies support a role for adenosine in AV block
with infarction [64–66], and data also supports A1AR involvement in
atrial ﬁbrillation in infarct and coronary artery bypass graft patients
[67,68]. A recent report from Alvarado-Tapias et al. identiﬁes
markedly augmented arrhythmogenesis with adenosine in an animal
model of chronic Chagas cardiomyopathy [69]. The actions of
adenosine are also consistent with a role in sick sinus syndrome
[70], though mechanistic involvement is yet to be fully established.
The poorly selective AR antagonists aminophylline and theophylline
do suppress symptoms in aged patients with this disorder [71,72].
Decay of ventricular ﬁbrillation is accelerated by A1AR antagonism in a
swine model [73], though this effect of endogenous adenosine does
not impact on short-term outcomes [74]. On the other hand, beneﬁcial
anti-arrhythmic effects of preconditioning (PreC) in animal models
may involve the actions of endogenous adenosine [75].
Given potent electrophysiological actions of A1ARs, and evidence of
involvement in arrhythmogenesis, it is not surprising that varied A1AR
agonists have been trialed as anti-arrhythmics. Adenosine itself is
employed as an effective treatment for termination of paroxysmal
supraventricular tachycardia (Adenocard), and has also been used ‘off-
label’ as an electrophysiological diagnostic aid. More select A1AR
agonists such as tecadenoson ((2R,3S,4R)-2-(hydroxymethyl)-5-(6-
((R)-tetrahydrofuran-3-ylamino)-9H-purin-9-yl)-tetrashydrofuran-
3,4-diol) and selodenoson ((2S,3S,4R)-5-(6-(cyclopentylamino)-9H-
purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide)
have been trialed as type-IV anti-arrhythmics, being shown to be safe
and well tolerated in Phase I trials, and effectively targeting supraven-
tricular tachycardia and atrial ﬁbrillation respectively [76]. With
ongoing research efforts in this area, new AR-based approaches to the
treatment and diagnosis of arrhythmias are likely to emerge over the
coming years.
2.3. Vascular control
Adenosine and its receptors modify vascular tone, and may play a
role in vasculogenesis/angiogenesis and vascular remodeling (the latter
discussed under Section4). In their early studyDrury and Szent-Györgyi
also reported on vasoregulatory effects of adenosine [53]. An ‘adenosine
hypothesis’ of coronary vasoregulation was later forwarded in 1963,
proposing regulation of coronary tone via purine signals coupled to
cellular energy state [77,78]. The coronary vasoregulatory functions of
adenosine and ARs have been studied intensely since that time, and are
still debated. Despite evidence that ARs and adenosine play little role in
control of basal coronary tone or functional hyperemia [79,80], and are
only relevant during signiﬁcant O2 supply:demand mismatch, this
remains contentious. Studies in human hearts reveal decreased basal
ﬂowwith increased coronary resistance and O2 extraction following AR
antagonism [81,82]. In sedatedpigs enhanceddeaminationof adenosine
increases baseline coronary tone [83], and limits early hyperemiaduring
ß-adrenergic stimulation [84]. Duncker et al. also found that AR
antagonism shifts the relationship between MVO2 and coronary
resistance in conscious pigs, implicating a role for endogenous
adenosine in control of basal tone and inﬂuencing (but not being
essential for) exercise-dependent hyperemia [85]. Mouse gene knock-
out studies also implicate ARs in control of coronary tone, albeit in vitro
[15,26]. While a role in reactive or hypoxic hyperemia is well
established, the importanceof adenosine andARs in regulating coronary
tone under physiological conditions in vivo remains unclear.
The A2A and A2BARs are expressed in both smooth muscle and
endothelium, andcontribute towhat appears tobeprimarily endothelial-
dependent, but also direct smooth muscle, relaxation. The A2A andA2BARs affect coronary vasodilatation in a species-speciﬁc manner —
A2AARs play a role in human [86], pig [87], guinea pig [88,89] andmouse
[90], whereas A2BARs are also active in humans [91] and may contribute
in the rat [92]. There is evidenceofA2BAR-mediatedcoronarydilatation in
mice, though this predominatesonlywhenA2AARs aredeleted [93]. As an
aside, the observation that deletion of the A2AAR leads to compensatory
up-regulation of coronary A2BARs itself supports an important regulatory
function of A2AARs.
Second messenger and effector involvement in coronary A2AR
responses remains to be fully detailed, particularly in human vessels.
The A2A and A2BAR couple to Gs to activate adenylate cyclase, cAMP
accumulation and PKA activity, and these cAMP signals appear
important in coronary responses. Other pathways have nonetheless
been implicated in AR-mediated coronary dilatation, including p38-
MAPK in murine vessels [94] and inositol 1,4,5,trisphosphate
signaling in pig vessels [95]. Coronary vasodilatation via adenosine
has been linked to NO and KATP channel activation in animal models
[91,96,97]. In human coronaries A2BAR responses also involve KATP
channels, but may not rely on NO [91].
While the vasoactive properties of the A2 sub-types have been
most extensively studied, there is also evidence for coronary
responsiveness to A1 and A3ARs. The A1ARmay trigger direct coronary
constriction and inhibit A2AR-dependent dilatation [26,86]. This is
consistent with co-expression of A1, A2A and A2BARs in coronary
vessels [98]. The A3AR has also been attributed with vasoregulatory
properties, although it is not clear how such responses are mediated
since expression in vascular cells is very low or not detected. Wang
and colleagues observe mRNA expression for all 4 ARs in porcine
coronary vessels, and protein expression of all except the A3AR [98].
This reﬂects the somewhat elusive nature of cardiovascular A3ARs,
which also appear to be minimally expressed in myocytes despite
mediating powerful cardioprotection. Coronary vascular effects of
A3ARs may involve indirect signaling through non-vascular cells such
as mast cells. Duling and colleagues describe a role for mast cell
activation in A3AR-dependent constriction of peripheral vessels (via
release of histamine and thromboxane) [99]. Degranulation of mast
cells by A3ARs appears highly species-dependent; however, there is
also some evidence of A3AR expression in aortic smoothmuscle [100],
while pharmacological approaches hint at functional coronary A3ARs
[101–103]. Talukder et al. acquire evidence from knockout mice that
the A3AR inhibits A2AAR-dependent dilatation [104]. On the other
hand, there is evidence that coronary responses to A3AR agonists may
actually involve activation of A2AARs [105]. Other studies report
coronary insensitivity to A3AR agonists in guinea pig [89] and mouse
[106]. Available data is thus mixed regarding vascular effects of A3ARs
in different beds and species, with further interrogation required.
As noted above, studies of AR gene deletion identify alterations in
coronary vasoregulation and support regulatory roles of endogenous
adenosine. Phenotypic outcomeswith CD73 deletion include a decline
in baseline coronary ﬂow, supporting vasodilatation by extracellular
adenosine [15]. However, there was no shift in reactive hyperemia,
arguing against an essential contribution of this adenosine pool to that
response (or compensation via other mediators). Baseline coronary
tone was unaltered or slightly reduced with A1AR knockout [26,107],
supporting some A1AR-dependence of basal tone, though it is unclear
whether A1AR deletion modiﬁes tone directly or by altering A2A/2BAR
responsiveness. Deletion of the A2AAR impairs adenosine-mediated
dilatation, but does not consistently modify basal tone [93,108],
though induction of A2BARsmay compensate [93]. Again, a mix of data
exists regarding AR control of coronary tone in murine models.
2.3.1. Peripheral vascular control
The peripheral vasculature impacts on the heart through shifts in
pre- and afterload. Exogenous adenosine modiﬁes vascular tone in
peripheral vessels, and studies of gene deletion support AR control of
peripheral tone and blood pressure. Ledent et al. reported that A2AAR
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whether this phenotype arises from local vascular or central/renal
changes is uncertain, as the A2AAR may modify nervous control of
pressure [110]. Other gene deletion studies suggest some impact of
ARs on blood pressure control, though again thesemay reﬂect shifts in
central and renal blood pressure regulation rather than direct vascular
effects. Deletion of A1ARs also elevates blood pressure, which has been
linked to altered renin release [111]. Knockout of the A3AR increases
cardiac and vascular cAMP levels without altering baseline blood
pressure, although animals are sensitized to systemic hypotension in
response to adenosine, supporting an inhibitory effect of the A3AR
[112].
2.3.2. Pathobiology
There is evidence of alterations in AR-dependent vascular control
in disorders relevant to coronary or peripheral circulations. Several
studies support impaired AR-mediated vasoregulation in hyperten-
sion [113,114], though this may reﬂect broad-spectrum inhibition of
endothelium-dependent vasomotor control. The anti-hypertensive
activity of adenosine and AR agonists [115], and induction of
hypertension with AR antagonism or knockout [109,116], does
support roles for adenosine in regulating peripheral tone and
pressure. However, whether altered AR responses are important in
progression of hypertensive disease is not clear. In a gene association
study no linkage was detected between arterial blood pressure and
variants of A1ARs, A2AARs, or adenosine deaminase [117]. Effects of
ARs on central and renal control mechanisms are more likely
contributors to hypertension than shifts in direct vascular responses
[113]. Nonetheless, AR control of remodeling and vessel growth may
well play a role in the vascular tissue changes associated with
hypertension, as supported by vascular remodeling in response to
inhibition of endogenous adenosine [116].
There is also evidence of altered vascular AR signaling with
elevations in dietary salt and in early stage metabolic syndrome.
Nayeem et al. report on potential adaptation of AR control, with down-
regulation ofA1ARs (reducing arterial constriction) andup-regulation of
A2AARs (producingKATP channel dependentdilatation) inmiceonahigh
vs. normal salt diet [118]. Bender et al. have also found that AR
mechanisms of coronary dilatation are shifted prior to overt decrements
in coronary dilator reserve in early metabolic syndrome. The relevance
of these changes and their roles in disease pathogenesis are as yet
unclear [119].
Diabetes, which promotes cardiovascular disease and worsens
outcomes, is associated with impaired vascular AR responses [114].
Vascular responsiveness to a variety of stimuli is impaired in diabetes,
likely revolving around ROS-dependent endothelial dysfunction
[120]. Thus, ARs are not selectively modiﬁed, and the roles of
individual vascular changes in the pathobiology of diabetes have not
yet been clearly established. Diabetes modiﬁes other AR responses
that may be relevant to cardiac pathology, including protective
conditioning responses attributed to adenosine.
Investigations reveal AR-mediated coronary vascular protection
that may be relevant to adenosines' role in disease. Exogenous AR
agonists can limit coronary dysfunction and damage following
ischemic insult [121,122]. In addition, AR antagonism exaggerates
coronary vascular injury in rodents, supporting a role for intrinsic
A1AR activity in protecting the vasculature during periods of stress
[122]. This vasoprotection, which preserves endothelial function and
vascular control, may also be relevant to the impact of ARs on vascular
lesion development and re-stenosis.
The vasoregulatory properties of ARs have been capitalized upon
clinically in humans, although for purposes of diagnosis rather than
treatment of coronary artery disease. Adenosine (Adenoscan) has been
employed as a substitute for exercise stress in myocardial perfusion
imaging. Its use is limited somewhat by side-effects, including AV
conduction delay, chest pain, and bronchospasm. These issues may bemitigated by development of more selective A2 sub-type agonists, and
several A2AAR selective agonists have been trialed (binodenoson,
apadenoson) or recently approved for such use (regadenoson).
2.4. Regulation of myocardial substrate metabolism
Adenosine exerts signiﬁcant effects on glucose metabolism and
fatty acid availability. These actions may be important in modulating
myocardial responses to hypoxic or ischemic stress, and potentially
play roles under physiological conditions (e.g. sympathetic activation)
and in disease (e.g. diabetes). Observations regarding effects of
adenosine on glucose metabolism have been conﬂicting, and
responses in humans are yet to be assessed. A number of studies
support adenosine and AR stimulation of myocardial glucose uptake
[123–127], a response that may reﬂect potentiation of insulin's
actions [128–130]. Indeed, some work indicates that the effects of
insulin require functional AR activity [130]. However, there is also
evidence of distinct mechanisms underlying the effects of adenosine
and insulin on glucose uptake [125]. Responses to AR antagonists do
implicate a role for endogenous adenosine in promoting glucose
uptake under normoxic [126,127,131] and hypoxic [124,131] condi-
tions. Beneﬁcial effects of cardiac PreC during ischemia-reperfusion
have also been linked to enhanced glucose utilization, which is
dependent upon AR activity [132]. The effects of adenosine appear to
be independent of coronary ﬂow, work rate or adrenergic activity, and
while initially thought to involve A1ARs may additionally involve the
A2AAR. In a recent study in fetal sheep, Maeda and Koos [131] found
that intrinsic A1AR (but not A2AAR) activity reduces plasma glucose,
lactate and insulin levels, whereas exogenous adenosine increases
plasma glucose and lactate via A2AARs (a response countered by A1AR
activity). Hyperglycemia with hypoxia was partly mediated by A1 and
A2AAR activation. They conclude that A1AR activity facilitates at least
12% of normoxic glucose utilization.
In contrast to such studies, Gao et al. reported that AR blockade
increases glucose uptake under normoxic and low-ﬂow ischemic
conditions, supporting inhibition of utilization by endogenous
adenosine [133]. Fraser et al. also present evidence that A1ARs may
partially inhibit glycolysis and thus improve coupling of glycolysis to
glucose oxidation, reducing H+ generation and limiting post-ischemic
damage and dysfunction [134]. Reasons for differing observations
regarding ARs and glucose metabolism are unclear, though a majority
of studies support facilitated glucose uptake under most conditions.
As indicated in the work of Fraser et al., however, the balance of
glycolysis vs. glucose oxidation (rather than uptake per se) is also an
important regulatory factor.
Effects of adenosine in other organs will impact on cardiac
substrate handling — hepatic glucose can be liberated via intrinsic
A3AR agonism, for example, which might serve to mobilize glucose
during ischemia/hypoxia [135]. Cardiac substrate metabolism will
also be sensitive to anti-lipolytic actions of adenosine. Activation of
adipocyte A1ARs inhibits cAMP generation and lipolysis [136,137].
Reducing the release and availability of fatty acids has the potential to
improve cardiac insulin resistance and glucose handling, and
dyslipidemias. For example, Shearer et al. recently showed that a
partial A1AR agonist lowers circulating fatty acids and improves
cardiac glucose clearance in amodel of diet-induced insulin resistance
[138]. Anti-lipolytic A1AR-based therapies tomodulate lipid levels and
potentially insulin resistance have entered early-phase clinical trials.
2.4.1. Pathobiology
The role of AR-dependent control of glucose uptake (and lipolysis) in
pathological conditions such as diabetes and hyperlipidemia has not
been extensively assessed. Adenosine responses themselves may well
be regulated by changes in substrate levels. For example, AR expression
in cardiacﬁbroblasts is sensitive to glucose and insulin,with glucose up-
regulating A1 and A2BARs and repressing A3ARs, whereas insulin
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between AR function and circulating substrate that may be relevant
to diabetes and metabolic syndrome. Experimental streptozotocin-
dependent diabetes is associated with up-regulation of cardiac A1 and
A3ARs [140], an effect countered by insulin treatment. As already noted,
vascular responses to ARs are also impaired in diabetes [114], and
modiﬁed in earlymetabolic syndrome [119]. However, the contribution
of altered AR responses to these disorders is yet to be established.
Though not a direct cardiac effect, shifts in adipocyte lipolysis and
thus fatty acid availability clearly impact on the heart and vessels, and
there is evidence that AR control of lipolysis is modiﬁed in obesity (a
major and growing risk factor for heart disease). Altered control of
lipolysis in obese Zucker rats appears to involve enhanced A1AR-
dependent inhibition of adenylate cyclase [141]. This is consistent
with evidence of enhanced adipocyte A1AR sensitivity in ob/ob mice
[142]. Such effects could contribute to progression and maintenance
of obesity. A more recent study by Barakat et al. identiﬁes increased
A1AR expression in visceral adipose tissue from African-American vs.
Caucasian women, which may lead to enhanced A1AR sensitivity and
reduced fat mobilization in the former [143]. The authors speculate
that this may underpin maintenance of obesity in African-American
women, though this has yet to be tested. On the other hand, the work
of Kaartinen et al. in human adipocytes reveals impaired AR-mediated
adenylate cyclase/cAMP inhibition in cells from obese subjects,
involving reduced A1AR expression and linked to enhanced adipose
tissue adenosine [144]. The authors suggest that augmented adeno-
sine may explain inhibition of lipolysis in situ in obesity, while AR
desensitization may explain diminished adenosine responses in cells
in vitro. Nonetheless, a subsequent study has reported that weight-
loss after gastric bypass or gastroplasty leads to normalization of A1AR
inhibition of lipolysis [145]. This indicates that shifts in AR control
may actually be secondary to development of obesity, which does not
preclude a role for such changes in obesity maintenance. Aging may
also enhance the anti-lipolytic effects of A1ARs: Hoffman et al. show
that reduced adrenergic activation of lipolysis in aged rodents
involves enhanced inhibitory effects of endogenous adenosine [146].
Such changes might contribute to age-related shifts in substrate
metabolism and availability, and facilitate age-dependent obesity.
Further work is required to clarify the roles of ARs in regulating
lipolysis and glucose handling in different disease states, and their
relevance to disease onset and progression.
As noted above, A1AR-based therapies have been trialed for
manipulating free fatty acid (FFA) levels and improving insulin
sensitivity in diabetes, though none have received regulatory approval
as yet. For example, tecadenoson, although not initially developed as
an anti-lipolytic agent, has been shown to reversibly lower FFA levels
in a pilot Phase I study by CV Therapeutics. Similarly, the agent ARA
([1S,2R,3R,5R]-3-methoxymethyl-5-[6-(1-[5-triﬂuoromethyl-pyri-
din-2-yl]pyrrolidin-3-[S]-ylamino)-purin-9-yl]cyclopentane-1,2-
diol) also lowered fatty acid levels in a Phase I clinical study, though
tolerance emerged rapidly [147]. While this general approach to
lowering FFAs and improving insulin resistance and diabetes is
validated by experimental and small trial data, challenges to effective
A1AR agonist-based therapy include widespread receptor distribution
(rendering site- or organ-speciﬁc targeting difﬁcult), and emergence
of tolerance due to receptor down-regulation/desensitization (limit-
ing efﬁcacy of long-term anti-lipolytic therapy). Such problems,
relevant to AR pharmacotherapy in other organ systems and
disorders, may be overcome to some degree through development
of partial AR agonists.
3. Retaliation
Under conditions of severe metabolic insult such as ischemia or
hypoxia, beneﬁcial effects of adenosine on function (heart rate,
contractility) and energy supply (coronary ﬂow, substrate metabo-lism) are insufﬁcient to restore the balance between cardiac energy
supply and demand (Fig. 1). Under these conditions the so-called
‘retaliatory’ functions of adenosine may come to the fore, mediating
acute and delayed cytoprotective responses that limit reversible and
irreversible forms of injury. Adenosine and its receptors have been
extensively studied in the context of protection against cellular injury
during ischemia-reperfusion [148–151]. Greatly enhanced levels of
extracellular adenosine activate acute cytoprotective signaling via
multiple AR sub-types [148,149]. Adenosine is also involved in
delayed or adaptive PreC responses [150,151]. Studies in different
models and species document powerful protection against infarction
and myocyte injury via either pre- [152–159] or post-ischemic [160–
169] AR activation. While early work identiﬁed and focused on
protective functions of the A1AR, cardioprotective properties have
been identiﬁed for all 4 AR sub-types [149,150].
3.1. AR contributions to protection during and following ischemia
Cardioprotection was initially thought to be primarily mediated
during ischemia, and there is evidence that ischemic AR activity is
important in expression of protection: Toombs et al. found that AR
antagonism during ischemia eliminated AR protection [170]; speciﬁc
protective effects of A1ARs are evident during ischemia vs. reperfusion
[132,171,172]; and AR activity modiﬁes substrate use, energy
metabolism, ionic overload, and contracture during ischemia
[132,173,174]. Commensurate with these ﬁndings, protection via
the A1AR has been shown to involve receptor activity prior to and
during ischemia, but not during reperfusion [153,154,174–176], and
ischemic PreC requires intrinsic A1AR activity during but not following
ischemic insult [154].
Despite minimal cardiac A3AR expression, pharmacological evi-
dence also supports A3AR-dependent protection in myocardium from
different species [158,168,172,177,178] including humans [156].
Protection is triggered with pre-ischemic A3AR activation
[156,158,159,167,178]. While A3AR effects, as for the A1AR, are
thought to predominate during ischemia, there is nonetheless
evidence that post-ischemic A3AR activity can also be protective
[167–169].
Contrasting work on A1 and A3AR responses, a number of studies
show that pre- or intra-ischemic A2A or A2BAR agonism does not
induce protection [153,167], whereas post-ischemic activity is highly
protective [160,162–166]. Indeed, recent work highlights an impor-
tant protective function for A2A [179–181] and A2BARs [14,182–184]
in post-ischemic myocardium that is relevant to conditioning
responses. Generally then, A1/A3AR activation of protection is
predominantly an ischemic event while A2A/A2BAR protection is
mediated during reperfusion. There may nonetheless be important
interactions between receptor sub-types in the mediation of cardio-
protection [149,150].
Based on ﬁndings regarding the A2BAR, Downey and colleagues
forward an intriguing model entailing PKC-dependent sensitization of
protective A2BARs [182–184]. They present evidence that cardiac
protection via PKC activation is A2BAR-dependent (locating A2BARs
downstream of PKC), and that PKC activation and PreC both
substantially lower the threshold for AR-mediated phosphorylation
of protective kinases. It is proposed that activated PKCδ targets a
particular A2BAR sub-type – A2B light4 – to enhance its sensitivity,
enabling activation by endogenous adenosine in early reperfusion.
This is underpinned primarily by data in rabbit hearts, though A2BAR
dependence of conditioning responses is supported by knockout
studies in mice [14]. Modulation of A2BAR sensitivity is also consistent
with PKC-dependent sensitization of A2AR responses in other cell
types [185,186]. As discussed below, this mechanism may contribute
to both PreC and postconditioning (PostC). Sensitization of A2BARs
may itself be AR-dependent — A1ARs activated during PreC or
ischemia [153,154,170,171,174–176] stimulate PKC, and there is
1420 J.P. Headrick et al. / Biochimica et Biophysica Acta 1808 (2011) 1413–1428also evidence that A1AR-triggered protection is dependent upon A2A/
A2BAR activity [187]. Interestingly, a recent preliminary report
describes novel expression of A2BARs on mitochondria rather than
the sarcolemma [188], whichmay be relevant to interactions between
A2BARs, signaling kinases, and other AR sub-types in cardioprotection.
Since interstitial adenosine (and inosine) levels achieved during
ischemia or hypoxia are sufﬁcient to substantially activate cardiovas-
cular ARs [174,189], it is predicted that intrinsic AR activity will
impact on myocardial tolerance to ischemic insult. This is borne out in
some studies assessing effects of AR blockade or deletion on ischemic
responses [14,107,161,170,171,175,190], although many others do
not identify shifts in intrinsic tolerance following AR inhibition. The
question of adenosines' importance to intrinsic ischemic tolerance
thus remains unresolved.
3.2. Roles of ARs in conditioning responses
Conditioning responses are of considerable interest, in unmasking
intrinsic cytoprotective mechanisms and as potentially useful thera-
peutic interventions. Considerable evidence has accumulated sup-
porting an essential role for endogenous adenosine in mediating PreC
and PostC responses. Liu et al. provided initial evidence that
endogenous adenosine mediates PreC [152], and other work conﬁrms
that antagonism of ARs or reductions in adenosine levels limits PreC in
multiple models and species [132,154,155,174,191–193]. In terms of
AR sub-types, early work supported A1AR involvement [152,155,191].
However, subsequent studies demonstrate that A3AR antagonism also
inhibits PreC [178,194], or identify contributions from both A1 and
A3ARs [195,196]. Studies in mice support abrogation of PreC with
A1AR knockout [197,198]. In terms of human myocardium, Walker
and colleagues reported mediation of PreC by ARs [199], Cleveland et
al. [200,201] conﬁrmed AR-mediated PreC in human tissue, and Tomai
et al. [202] described A1AR-dependent PreC in patients undergoing
coronary angioplasty. Activation of A1 and A3ARs induces PreC in
human atrium [156], and Ikonomidis et al. [203] demonstrated AR
dependence of protection in isolated human myocytes. Collectively, a
range of studies in animal and human tissue support roles for A1 and
A3ARs in triggering/mediating protection with PreC. That said, AR
activity during reperfusion is also important in PreC [161,193], and
recent work supports a crucial role for post-ischemic A2BAR activity in
both PreC and PostC [182–184].
The infarct-limiting effects of PostC are reduced with AR
antagonism or knockout [169,204], and data support roles for A2A
[169,205], A3 [169] and A2BARs [14] in PostC in mice, and A2BARs in
rabbits [182]. Protection via either PreC or PostC is blocked by post-
ischemic A2BAR antagonism in rabbits, and A2BAR agonism in early
reperfusion mimics this protection [182,184]. As already discussed,
Downey and colleagues propose that protection via conditioning
responses involves PKC-dependent sensitization of A2BARs and
subsequent A2B-mediated protection in early reperfusion [151]. Both
PreC and PostC may thus converge on A2BAR modulation and
activation of protective signaling in reperfused tissue [182–184].
This model contrasts data supporting inhibition of PostC in A2AAR
knockout mice [205], though it is tempting to speculate that A2BAR
sensitization might involve prior A1 or A2AAR activity. In support of
this, Xi et al. suggest that both A2A and A2BARs are required for
protection with PostC [206]. On the other hand, Eckle et al. found that
only A2BAR knockout inhibited PostC in mice, whereas deletion of the
other 3 sub-types was ineffective [14]. The importance and relevance
of A2BAR sensitization and signaling thus remains contentious and is
yet to be extensively interrogated in different models and species. One
small study presents evidence that, in contrast to this scheme,
functional AR sensitivity is unaltered by ischemia [207]. However, this
work only tested shifts in A1AR-dependent bradycardia (mediated by
nodal ARs and Gi control of IK,Ado) and A2AAR-dependent coronary
dilatation (mediated by vascular ARs, Gs signaling, KATP channels, andNO). The data are not representative of AR-mediated protective
signaling in ventricular myocardium. Sensitivities of A1AR mediated
bradycardia and A1AR-mediated protection can be dissociated, with
aging for example where the former is unchanged while the latter
decreases [208].
3.3. Pathobiology
If, as discussed previously, ARs and endogenous adenosine
are important in dictating intrinsic ischemic tolerance
[14,107,161,170,171,175,190], then AR activity will play a role in
outcomes from ischemic heart disease. This is supported by recently
described associations between variants of A1 and A3AR genes and
infarct size in patients with ischemic cardiomyopathy [209]. Some
disease states may also sensitize the myocardium to dysfunction/
damage by impairing AR and other GPCR-dependent protective
responses [210]. Diabetes, obesity, hypertrophy and hypertension
have all been shown to signiﬁcantly inhibit or entirely abrogate
intrinsic protection via PreC, PostC, ARs and other GPCRs [210,211].
Aging may induce similar changes [208], and other relevant
abnormalities may impact on or involve altered AR activity. For
example, effects of hyperhomocysteinemia (an independent risk
factor for cardiovascular disease linked to impaired ischemic
tolerance) in an animal model involve impaired A1AR activation by
local adenosine [212]. A general pattern emerges of impaired
receptor-triggered protective signaling in aged or diseased tissue,
predisposing hearts to injury and infarction. Such effects may
contribute to poor clinical translation of experimental protective
modalities targeting these paths [210,211]. One may speculate that
the impact of diseases such as diabetes on the heart and cardiovas-
cular mortality (increasing occurrence and worsening survival)
involves impairment of cytoprotective responses. It is also tempting
to speculate that age-related shifts in protective pathways reﬂect an
integral component of the aging process, since a decline in cellular
stress resistance is a deﬁning feature of the aged phenotype.
Despite potent protective effects of adenosine and ARs experi-
mentally, there have been relatively few trials of adenosine-based
cardioprotection in humans, and outcomes have been mixed. In the
acutemyocardial infarct study of adenosine (AMISTAD), a 3 h infusion
was trialed in infarct patients, with adenosine reducing infarction by
33% relative to placebo. In the sub-set of patients with anterior
infarcts, this reduction was greater at 67% [213]. These promising
outcomes led to AMISTAD II, testing effects of adenosine in ST-
segment elevationmyocardial infarction (STEMI) patients undergoing
reperfusion therapy. The larger trial showed a signiﬁcant 50% relative
reduction in infarct size with adenosine, yet no differences in the
longer-term primary end-points of heart failure development and re-
hospitalization [214]. A larger study may be required to determine
whether infarct reductionwith adenosine is associatedwith improved
long-term outcomes. Post-hoc analysis did ﬁnd that patients receiving
adenosine within 3 h of symptom onset exhibited reduced mortality
at 1 and 6 months and enhanced event-free survival, demonstrating
the critical nature of treatment timing [215]. The ADMIRE trial tested
differing doses of the A1/A2AAR agonist AMP579 in STEMI patients
undergoing angioplasty [216]. The trial showed no signiﬁcant effects
of treatment on the primary end-point of infarct size, nor on different
secondary end-points, although the highest dose of AMP579
employed was only equivalent to the lowest effective doses assessed
experimentally. The non-nucleoside A1AR agonist capadenoson
(BAY68-4986) has also been assessed in Phase II trials for use in
patients with stable angina and coronary heart disease, and Phase III
trials are at or near completion.
Trials of PreC- or PostC-based strategies indirectly assess the
therapeutic value of AR-dependent cardioprotection, given evidence
from animal and human myocardium that ARs are crucial to these
responses. Results of small trials of PreC and PostC are mixed, though
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[211,217]. Nonetheless, outcomes have been somewhat disappoint-
ing, and data is insufﬁcient to recommend widespread clinical use in
infarct patients [211,217]. One important factor that may limit clinical
translation of AR and conditioning-based cardioprotection is the
negative inﬂuence of age and disease on these responses [210,211].
Efﬁcacy of experimental protective interventions should be assessed
speciﬁcally in aged and relevant chronic disease models prior to
implementation of clinical trials.
4. Adaptation (and maladaptation)
Adenosine can mediate longer-term adaptive responses, including
the second or delayed window of protection with PreC — a hormesis
response to a mild stressor that generates prolonged cellular
resistance [148–151]. Adenosine also impacts on remodeling pro-
cesses in cardiac and vascular tissues, modulating cardiac ﬁbroblast
proliferation, collagen synthesis, extracellular matrix (ECM) remodel-
ing, myocyte apoptosis, and vascular genesis and development.
Modulation of inﬂammatory processes plays an important role in
these effects [32]. These actions may be important in adaptive/
maladaptive structural responses to hemodynamic, ischemic, oxida-
tive or other stressors. Effects of AR manipulation in these scenarios
support the potential value of AR-based therapies in hypertrophy,
heart failure and atherosclerosis/re-stenosis.
4.1. Myocardial remodeling and hypertrophy
Given effects of adenosine on the ECM, and on cardiac ﬁbroblast,
endothelial and smoothmuscle growth and apoptosis, local adenosine
changes during tissue stress are predicted to impact on repair and
remodeling in vivo. Cardiac ﬁbroblasts are an important mediator of
adverse remodeling, generating excess ECM proteins, ﬁbrosis and
contractile dysfunction, and ultimately heart failure. Adenosine
inhibits ﬁbroblast proliferation and collagen synthesis, thus limiting
remodeling and progression to failure. Studies from Dubey and
colleagues identify a speciﬁc role for the A2BAR in inhibiting ﬁbroblast
proliferation and collagen synthesis [218–220], conﬁrmed subse-
quently by A2BAR knockout and overexpression [221]. However, it is
important to note that other ﬁbroblasts may respond differently to AR
agonism — pulmonary ﬁbrosis in an adenosine deaminase deletion
model appears to be A2BAR-dependent [222], and A2AARs promote
collagen synthesis in skin ﬁbroblasts and hepatic stellate cells
[223,224]. Thus, adenosine can act via different AR sub-types to
either repress or promote ﬁbrosis in different tissues. Recent work
suggests that within the heart a combination of A2B and A2AAR
triggered cAMP-dependent signals contribute to suppression of
ﬁbroblast growth and ﬁbrosis, involving a speciﬁc Gs-adenylyl cyclase,
cAMP and Epac dependent path acting via PI3K [225,226].
Pro-inﬂammatory factors such as TNFα and IL-6 are implicated in
adverse remodeling and hypertrophy, and are sensitive to control by
ARs. For example, Feng et al. show that pro-inﬂammatory IL-6 (a
cytokine with pleiotropic effects on remodeling) is induced in cardiac
ﬁbroblasts by A2BARs in a PKCδ/p38-MAPK dependent manner [227].
Increased TNFα induces cardiomyopathy [228], and Wagner et al.
show that adenosine substantially limits myocyte TNFα expression
during inﬂammatory challenge via an A2AR sub-type (in rodent and
humanmyocardium), and induces IL-6 via A3ARs in rat but not human
tissue [229]. Adenosine and ARs also limit the generation of
inﬂammatory cytokines in invading or resident inﬂammatory cells,
in addition to myocytes and ﬁbroblasts [32].
Remodeling involves enzymatic degradation of the myocardial
ECM. Matrix metalloproteinases such as MMP-9 play a key role, and
adenosine differentially modulates MMP-9 secretion in different cell
types, activating macrophage MMP-9 secretion via A3ARs [230], and
inhibiting monocyte and neutrophil MMP-9 secretion via A2BARs andA2AARs, respectively [231,232]. The latter A2AAR effect may inhibit
detrimental remodeling after cardiac injury/infarction, when neutro-
phils are activated and adenosine levels rise substantially. The effects
ofMMPsmay be both cell- and concentration-dependent— Velot et al.
[230] speculate that low levels of MMP-9 released from macrophages
may facilitate revascularization, whereas high levels released from
neutrophils degrade the ECM. Thus, A3AR activation of low-level
macrophage secretion may be beneﬁcial, just as A2A and A2BAR
inhibition of neutrophil MMP secretion may limit ECM degradation.
Other determinants of cardiac structure and function are also
sensitive to AR activity. For example, Yuan et al. show that A1 and
A3AR agonism increases cardiac ANP secretion [233,234], and ANP is
known to modulate myocyte apoptosis, oxidant stress, ﬁbrosis and
hypertrophy [235].
Exogenous AR agonists exert anti-remodeling/hypertrophic actions
in different disease models, with all receptor sub-types implicated. Gan
et al. [236] provide evidence for anti-hypertrophic effects of A1, A2A, and
A3ARs in phenylephrine-induced hypertrophy, involving repression of
NHE1 expression and shifts in G-protein signaling and immediate early
gene responses. Stimulation of A1ARs attenuates both hypertrophy and
dysfunction in an experimental pressure-overload model [237]. Long-
term stimulation of A2BARs following infarction inhibits development of
ﬁbrosis in non-infarcted myocardium, and enhances contractile
function [238]. This approach also inhibits myocyte apoptosis in remote
myocardium, even when commenced post-infarction [239]. Signaling
involvement has yet to be fully elucidated, though Gαq andmodulation
of pro-apoptotic PKC-δ/p38-MAPK signaling and Badmay be important
[239]. Anti-hypertrophic effects of ARs may also involve distinct KATP
channel activation — sarcolemmal KATP channels for A1ARs vs.
mitochondrial channels for A2A and A3ARs [240].
4.1.1. Pathobiology
There is ample experimental evidence of alterations in adenosine
levels, handling and receptor signaling in post-ischemic, hyperten-
sive, hypertrophied and failing myocardium in animal models.
Whether these changes reﬂect mechanistic involvement, compensa-
tory or adaptive changes, or non-speciﬁc targets of disease, has yet to
be established. The AR system may be beneﬁcially modulated in
response to hypertrophy [241], with up-regulation of A1, A2A and
A3ARs that, when activated, counter development of hypertrophy
[236]. In a model of compensated pressure-overload hypertrophy,
increased interstitial adenosine is accompanied by increased protec-
tive A1AR expression. However, overexpression is no longer evident
after transition to failure [242], suggesting secondary rather than
primary involvement. Shifts in A1AR expression may nonetheless be
relevant to disease progression, as excess A1AR expression can induce
cardiomyopathy, cardiac dilatation, hypertrophy and dysfunction
(dependent upon the timing of expression changes) [243]. In addition,
cardiac dysfunction in response to TNFα and in models of overload or
failuremay involve increased A1AR expression and reduced adenosine
levels, contributing to A1AR dysfunction [244].
Elevations in cardiac adenosine levels and reduced adenosine
deaminase activity have also been documented in heart failure
patients, together with reduced transcription of A2A, A2B and A3ARs
[245]. Increased adenosine can be related to shifts in deaminase and
nucleotidase activities, and may reﬂect compensation for impaired AR
signaling. Indeed, augmenting endogenous adenosine via transport
inhibition can limit severity of heart failure, supporting a role for
altered AR signaling in failure pathogenesis [245]. Similarly, augment-
ing endogenous adenosine prevents development of abnormal
ventricular ﬁlling, adrenergic dysfunction, and remodeling in hearts
from rats subjected to pressure-overload [246].
Studies of gene deletion in mice provide more direct evidence of a
role for endogenous adenosine and intrinsic AR activity in develop-
ment of hypertrophy and dysfunction/failure. Deletion of CD73
increases cardiac ﬁbrosis and hypertrophy with pressure-overload,
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sion [247,248]. This supports an important role for endogenous
adenosine (generated in the extracellular space) in preventing
maladaptive remodeling. Knockout of the A3AR did not exacerbate
dysfunction, but rather was found (unexpectedly) to reduce oxidative
stress and induce protection against hypertrophy and ﬁbrosis [248].
Interestingly, A1AR knockout failed to modify hypertrophy and
dysfunction yet signiﬁcantly increased mortality. Thus, endogenous
adenosine does exert beneﬁcial actions, yet these appear to be
countered (paradoxically) by A3AR activity in this model.
Despite evidence for beneﬁt from all 4 AR sub-types in models of
hypertrophy and failure, there are at present no direct cardiac-
targeted AR therapies for heart failure. However, trials have been
undertaken (e.g. for BG9719) or are underway (e.g. BG9928, KW3902)
into the therapeutic value of A1AR antagonism in acute decompen-
sated heart failure with renal impairment. This pharmacological
approach of renal A1AR antagonism reduces the detrimental impact of
ﬂuid retention/edema through promoting renal vasodilatation,
ﬁltration and diuresis. While effects of ARs on ﬁbroblast growth and
tissue remodeling suggest considerable potential for other AR-based
approaches in hypertrophy/heart failure, these responses are yet to be
extensively assessed in human tissue and different disease states.
4.2. Vascular genesis, growth and remodeling
Adenosine and ARs not only regulate vascular tone, but also
signiﬁcantly modulate vessel growth [249]. Evidence indicates that
adenosine plays an important role in neovascularization (including
angiogenesis and vasculogenesis). A variety of in vivo studies in
humans and animals demonstrate myocardial capillary proliferation
in response to either exogenous adenosine [250,251] or augmented
endogenous adenosine [252–254]. It appears that all 4 AR sub-types
play a role in angiogenesis and vasculogenesis [255], involving both
direct and indirect effects on endothelial, smooth muscle, ﬁbroblast,
and immune cells [256].
Adenosine promotes vessel growth via multiple mechanisms:
adenosine is mitogenic and stimulates vascular endothelial cell
proliferation, together with migration and tube formation in vitro
[249]; adenosine increases levels of pro-angiogenic molecules (e.g.
VEGF, angiopoetin-1, IL-8) in endothelial cells, monocytes and
macrophages; and adenosine promotes endothelial progenitor cell
adhesion and homing. While elevated adenosine levels in hypoxia or
ischemia may mediate such effects, these pathological angiogenic
stimuli also promote expression of relevant ARs. Ahmad et al. [257]
document pro-angiogenic effects of A2AAR activity in pulmonary
vessels, and identify a hypoxia-responsive element proximal to the
transcription-start site of the A2AAR gene that is speciﬁcally targeted
by HIF-2α. Thus, hypoxic stimulation of vessel growth may involve
HIF-2α sensitive A2AAR expression with subsequent A2AAR-triggered
growth. Additionally, Gessi et al. [258] show that adenosine can
stimulate HIF-1α expression via all AR sub-types. The hypoxic
stimulus for angiogenesis may thus revolve around AR induction of
hypoxia-sensitive regulators such as HIF-1α, and subsequent induc-
tion of pro-angiogenic ARs in a positive-feedback manner. Similarly,
macrophage A2BAR expression is enhanced in response to arterial
injury, and regulates inﬂammatory cytokine release that impacts on
vascular growth/remodeling [259].
In vitro, adenosine stimulates endothelial cell migration, prolifer-
ation, and tube formation, which is critical to capillary network
formation [249,257]. These effects are observed with adenosine levels
achieved during hypoxia or ischemia, and it is estimated that local
adenosine may in fact mediate 50–70% of angiogenic responses to
these stimuli [249]. Adenosine stimulates endothelial cell growth
through A2A and A2BARs [257,260], while the A2BAR appears to be
anti-mitogenic in vascular smooth muscle [261]. Other recent work
indicates that A1AR activation is mitogenic in coronary smoothmuscle[262,263]. Thus, the AR expression proﬁle within different vascular
beds and cells, coupled with differential AR sensitivities, may dictate
the precise mitogenic responses of smooth muscle and endothelial
cells to adenosinergic stimuli.
The primary angiogenic action of adenosine involves modulation of
expression of both pro- and anti-angiogenic substances in vascular and
immune cells. Adenosine stimulates endothelial release of IL-8, bFGF,
and VEGF in an A2BAR-dependent manner, and inhibits release of anti-
angiogenic thrombospondin-1 via A2AAR activity [264,265]. Ernens et al.
show that A2AARs trigger VEGF production in human macrophages
[266], highlighting adenosine as a unique pro-angiogenic molecule
potentially useful in stimulating cardiac repair. In addition, adenosine
triggers A2B/A3AR dependent IL-8, VEGF and angiopoetin-1 expression
in mast cells [267], and A1ARs trigger VEGF release from monocytes to
activate vessel growth [256]. Inﬂammatory cell control of angiogenesis
may be uniquely regulated by ARs, as Leibovich and colleagues
show that A2AAR activation switches macrophage phenotype from
pro-inﬂammatory to pro-angiogenic/VEGF secreting [268]. The pro-
angiogenic inﬂuence of the A2AAR is strongly supported by impaired
vessel formation in healing wounds in A2AAR knockout mice [269].
Recently Ryzhov et al. [270] demonstrated a role for adenosine in
promoting endothelial progenitor cell homing to coronary endothe-
lium, involving A1 and A2BAR activity and induction of endothelial P-
selectin. Adenosine may therefore also stimulate vessel formation and
growth through facilitated progenitor homing. Nonetheless, there
remains controversy regarding roles for ARs in these processes. For
example, A2BAR deletion enhances mesenteric artery adhesion (with
augmented endothelial adhesion molecules), suggesting that A2BARs
normally suppress endothelial adhesion [271]. Ongoing research
using A2BAR-deﬁcient mice should aid in delineating these processes,
though relevance to the human has yet to be established.
Vascular growth and remodeling requires orchestrated shifts in
apoptosis, and adenosine may not only promote growth but also
selectively modulate vascular death: endothelial apoptosis is inhib-
ited by A2AARs [272] and by A1AR signaling [273]. On the other hand,
Peyot et al. [274] present evidence that A2BARs facilitate smooth
muscle apoptosis, in line with enhanced death in response to
adenosine in cultured endothelial cells [275]. Differing AR expression
patterns may facilitate modulation of apoptosis in endothelial vs.
smooth muscle cells. However, the latter studies also assess highly
artiﬁcial scenarios of exposure to supra-physiological adenosine levels
(up to 1 mM) for 24 h, with enhanced apoptosis evident after 8 h
[274]. We are unaware of in vivo scenarios in which vascular ARs
would be exposed to such high adenosine levels (N10 μM) for several
hours or more. These studies, as with other work on A3AR-triggered
apoptosis, reﬂect cell death responses to prolonged and profound AR
agonism that may have little relevance in vivo.
4.2.1. Pathobiology
Animal studies show that endogenous adenosine promotes
vascular growth in vivo [252–254], and plays a major role in
angiogenesis in response to reductions in oxygenation [249].
Adenosine is also implicated in atherosclerotic processes in human
cells [258,276], and may play a role in vascular growth/remodeling
under other conditions, including re-stenosis. Edwards et al. found in
a pig model that A1AR expression is increased within stents, and that
A1AR activation increases smooth muscle cell proliferation [277].
Thus, inhibition of A1AR signaling holds some promise in the
management of in-stent stenosis, supported in principle by the
work of Kang et al. with A1AR antagonist eluting stents [278].
In the context of atherosclerosis, the work of Gessi et al. indicates
that A2B, A3 or mixed A2B/A3AR antagonists may be useful in blocking
key steps in plaque development [258]. Reiss et al. show that A2AARs
stimulate expression of proteins involved in reverse cholesterol
transport, and inhibit foam cell formation [276]. Smooth muscle
cells contribute to inﬂammatory signaling and ECM remodeling
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A2BAR knockout augments the effects of IFN-γ on collagen repression.
Thus, A2BARs may normally suppress these detrimental changes.
Effects of adenosine on vascular cells and remodeling involve AR
modulation of inﬂammatory cell signaling [32]. As already noted,
activation of A2AARs and toll-like receptors switches macrophages
from inﬂammatory to angiogenic phenotypes, involving induction of
the A2AAR together with VEGF and IL-10, and repression of TNFα and
IL-12 [268,280]. The A3AR has also been shown to inhibit IFN-γ
induced STAT1 phosphorylation and macrophage activation [281].
Since STAT1 is key to IFN-γ inﬂammation and foam cell transforma-
tion, this response might also be targeted in vascular disease.
However, despite evidence intrinsic A3AR activity can impede foam
cell formation in vitro [258], analysis of the effects of AR deletion
suggests no impact of the A3AR on atherogenesis in animal models of
diet-induced atherosclerosis and femoral artery injury [282].
A number of studies identify roles for CD73 (and thus extracellular
adenosine) in vascular pathology, stemming largely from modulation
of inﬂammatory processes. Initial analysis of CD73 deletion docu-
mented exaggerated platelet activation and leukocyte adhesion to
vascular endothelium [15], while later work revealed exaggerated
neointima formation following vascular injury [17]. More recently,
CD73 deletion has been shown to modify progression of cardiac
allograft vasculopathy via associated changes in A2BAR expression,
leading to increased transendothelial lymphocyte migration and
inﬂammation [18]. Deletion of CD73 also enhances pro-inﬂammatory
responses in human endothelium [16]. Endothelial targeting and
control appears critical to AR effects: inhibition of atherosclerosis by
endogenous adenosine involves maintenance of endothelial cells in a
non-activated quiescent state [283]. These studies collectively support
an important role of endogenous adenosine and ecto-nucleotidase
activity in regulating vascular responses to injury and inﬂammation,
which may ultimately be important in progression of re-stenosis and
atherosclerosis. Further research in human tissue and relevant disease
models is needed to clarify the importance of these responses in
human atherosclerosis.
5. Conclusions
The roles and functions of adenosine and its receptors have
expanded considerably as research progresses and the tools of gene
deletion or expression have been applied to interrogate these
receptor systems. Adenosine released in response to perturbations
in energy state, myocardial stress, or other stimuli mediates effects
that generally improve the balance between energy utilization and
energy supply (Fig. 1). Under conditions of extreme stress this
receptor system limits damage to constituent cells of the heart, and
modiﬁes subsequent cell and tissue growth and remodeling. Shifts in
AR signaling may play roles in the pathogenesis of a variety of
cardiovascular disorders, and it is therefore an attractive system for
therapeutic manipulation. However, the ubiquitous distribution of
ARs in the body represents a signiﬁcant challenge in this respect.
Profound cardiovascular effects may ultimately be achievable, yet
what is required are highly sub-type selective agents, and methods
to achieve desired actions at target organs/cells in the face of broad
AR distribution and problematic off-target effects. These challenges
are surmountable, underpinned by a more complete understanding
of the complex biomolecular interactions and functions of the AR
family and associated proteins in animal models and speciﬁcally in
humans.
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